CAS 1956356-56-1

KYA1797K

Description:

KYA1797K, identified by its CAS number 1956356-56-1, is a chemical compound that has garnered attention in pharmaceutical research, particularly for its potential therapeutic applications. While specific characteristics such as its molecular formula, structure, and physical properties may not be widely available, compounds in this category typically exhibit unique biological activity, often related to their interaction with specific biological targets. KYA1797K may possess properties such as solubility in various solvents, stability under certain conditions, and a specific mechanism of action that contributes to its efficacy in biological systems. As with many investigational compounds, detailed studies, including pharmacokinetics and toxicity assessments, are essential to fully understand its profile. Researchers often explore such compounds for their potential in treating various diseases, making them significant in the field of medicinal chemistry. For precise information, including safety data and specific applications, consulting scientific literature or databases dedicated to chemical substances is recommended.

Formula: C₁₇H₁₁KN₂O₆S₂

Synonyms:

• KYA1797K
• KYA1797K potassium salt >=98% (HPLC)
• (5Z)-5-[[5-(4-Nitrophenyl)-2-furanyl]methylene]-4-oxo-2-thioxo-3-thiazolidinepropanoic acid potassium salt
• CS-2581

KYA1797K

CAS: 1956356-56-1

Formula: C₁₇H₁₁KN₂O₆S₂

Purity: 96%

Color and Shape: Solid

Molecular weight: 442.5073

Ref: IN-DA01ENFQ

KYA1797K

CAS: 1956356-56-1

KYA1797K

Purity: ≥95%

Molecular weight: 442.51g/mol

Ref: 54-BUP05839

KYA1797K

CAS: 1956356-56-1

KYA1797K is a highly potent and selective inhibitor. Wnt/β-catenin IC50 is 0.75 μM through TOPflash assay.

Formula: C₁₇H₁₁N₂O₆S₂·K

Purity: 97.57% - 99.33%

Color and Shape: Solid

Molecular weight: 442.51

Ref: TM-T6868

KYA1797K

CAS: 1956356-56-1

KYA1797K is a small molecule that has been shown to activate β-catenin signaling pathways in cancer cells. KYA1797K activates the transcription-polymerase chain reaction (PCR) of genes involved in tumor growth, such as epidermal growth factor and PD-L1, which are not expressed in healthy cells. This drug also promotes the proliferation of pluripotent cells, which have the potential to differentiate into any cell type. KYA1797K has been shown to inhibit tumor growth in animal models and may be useful for the treatment of metastatic colorectal cancer.

Formula: C₁₇H₁₁KN₂O₆S₂

Purity: Min. 95%

Molecular weight: 442.51 g/mol

Ref: 3D-GDD35656